Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/SLFA-3
Statement of the Problem: The sheep erythrocyte membrane glycoprotein T11TS/SLFA-3 can form a ligand-receptor complex with CD2 present on immunocyte and exert stimuli for activation and proliferation. Regression of brain tumor with the application of T11TS indicates the probable role of microglia, the chief immunomodulatory cell within the brain compartment. In the present study microglial activation and immunophenotypic modulation were assessed in T11TS treated brain tumor-bearing animal models. Rat glioma models induced by chemical carcinogen ENU were treated with three consecutive doses of T11TS. Microglial cells from brain were isolated and assessed through E-rosette formation, SEM and FACS for CD2, MHC class II, CD25, and CD4. The preliminary indication of presence of CD2 on microglia through E-rosette formation was confirmed by SEM and FACS. MHC class II and CD2 single and double positive subpopulations exist, and their expression is also modulated in different doses of T11TS. A general trend of highest receptor saturation and microglial activation, measured through the activation marker CD25 and CD4 expression, was observed in 2nd dose of T11TS administration, which was then dampened via a complex immune feedback mechanism in the 3rd dose. Published in 2004.
Unable to display preview. Download preview PDF.
- 6.Le GS, Le DE, Labarriere N, Fonteneau JF, Viret C, Diez E, Jotereau F, LFA-3 costimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal, Eur J Immunol 24(4), 1322–31 (1998).Google Scholar
- 7.Sarkar S, Begum Z, Dutta SK, Chaudhuri S, Chaudhuri S, Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor: A new approach to biological response modifier therapy, J Exp Clin Cancer Res 21(1), 95–106 (2002).PubMedGoogle Scholar
- 13.Lantos PL, Chemical induction of tumors in nervous system. In NeuroOncology, edited by ThomasGT(Curchill Livingstone, New York, London, 1993), pp. 85–107.Google Scholar
- 16.Begum Z, Sarkar S, Mukherjee J, Ghosh A, Chaudhuri S, Chaudhuri S, Evaluation of anti-tumor property of specific and non-specific BRMs in experimental glioma by assessing the microglial cell function and phenotypic modulations, Cancer Biol Therapy 2, 356–63 (2003).Google Scholar
- 22.Fox DA, Hussey RE, Fitzgerald KA, Bensussan D, Daley JF, Schlossman SF, Reinherz EL, Activation of human thymocytes via the 50 Kd T11 sheep erythrocytes binding protein induces the expression of interleukin 2 receptors on both T3+ and T3- populations, J Immunol 134, 330–5 (1985).PubMedGoogle Scholar
- 24.Mukherjee J, Dutta S, Sarkar S, Begum Z, Ghosh A, Chaudhuri S, Chaudhuri S, Preclinical changes in immunoreactivity and cellular architecture during the progressive development of intracranial neoplasms and an immunotherapeutic schedule with a novel biological response modifier, the T11TS/ SLFA-3, Asian Pacific J Cancer Prev 3, 325–37 (2002).Google Scholar